Other Mereo BioPharma Programs
This page is intended for investors and commercial partners.
In addition to our two lead programs, we have out-licensed several other pre-clinical and clinical stage programs. There are still partnering opportunities in our non-core programs.
Vantictumab (OMP-18R5)
For the potential treatment of autosomal dominant osteopetrosis, another rare bone disease with a high unmet need.
STATUS: Partnered – āshibio
Leflutrozole (BGS649)
For the potential treatment of infertility in men with low serum testosterone.
STATUS: Partnered - ReproNovo SA
Navicixizumab (OMP305B83)
For the potential treatment of post-platinum ovarian cancer.
STATUS: Partnered – Feng Biosciences
Etigilimab (MPH313)
For the potential treatment of patients with advanced or metastatic solid tumors.
STATUS: Open to partnership
Acumapimod (BCT197)
For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
STATUS: Open to partnership